Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Democratizing data at Novartis through clinical trial data access.

Gabriel S Eichler1, Georges Imbert1, Janice Branson1

  • 1Novartis AG, Basel, Switzerland.

Drug Discovery Today
|March 1, 2022
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Data science in pharmaceutical R&D: the DISRUPT-DS industry roundtable.

Nature reviews. Drug discovery·2024
Same author

Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework.

Therapeutic innovation & regulatory science·2024
Same author

Aptamer Proteomics for Biomarker Discovery in Heart Failure With Reduced Ejection Fraction.

Circulation·2022
Same author

Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis.

BMC medical research methodology·2021
Same author

Coronary Artery Disease Polygenic Risk Score Identifies Patients at Higher Risk for Recurrent Cardiovascular Events in the CANTOS Trial.

Circulation. Genomic and precision medicine·2021
Same author

Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials.

Statistics in biopharmaceutical research·2021

Novartis streamlined clinical trial data access through the data42 program, enabling faster research and development (R&D) by automating most internal data requests. This risk-based approach overcame previous technical and policy barriers.

Area of Science:

  • Biopharmaceutical data management
  • Clinical trial data accessibility
  • Health informatics

Background:

  • Biopharmaceutical companies face challenges in accessing and utilizing clinical trial data due to technical, cultural, and policy barriers.
  • Limited data accessibility hinders research and development (R&D) efficiency and innovation.

Purpose of the Study:

  • To describe Novartis's data42 program, designed to overcome hurdles in clinical trial data access.
  • To explore the formulation of a risk-based data access approach involving diverse stakeholders.
  • To assess the impact of streamlined data access on R&D activities within Novartis.

Main Methods:

  • Implementation of the data42 program at Novartis.
  • Development of a risk-based framework for anonymized clinical trial data access.
Keywords:
Clinical trialsData DemocratizationData accessData lakeDigital transformation

Related Experiment Videos

  • Engagement of enterprise-wide stakeholders in defining data access policies.

    • Main Results:

    • Most internal clinical trial data requests are now automatically approved.
    • Significant improvement in the utilization of anonymized clinical trial data by R&D associates.
    • Successful mitigation of technical, cultural, and policy impediments to data access.

    Conclusions:

    • The data42 program demonstrates a successful model for enhancing clinical trial data accessibility and use within biopharmaceutical companies.
    • A risk-based, stakeholder-driven approach can effectively streamline data access and accelerate R&D.
    • The Novartis experience offers valuable insights for the broader biopharmaceutical industry seeking to improve data management and utilization.